Home  |  Contact

UniProtKB/Swiss-Prot P02751: Variant p.Tyr973Cys

Fibronectin
Gene: FN1
Variant information

Variant position:  973
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Type of variant:  LP/P [Disclaimer]
The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance

Residue change:  From Tyrosine (Y) to Cysteine (C) at position 973 (Y973C, p.Tyr973Cys).
Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.

Physico-chemical properties:  Change from large size and aromatic (Y) to medium size and polar (C)
The physico-chemical property of the reference and variant residues and the change implicated.

BLOSUM score:  -2
The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page

Variant description:  In GFND2.
Any additional useful information about the variant.

Other resources:  
Links to websites of interest for the variant.



Sequence information

Variant position:  973
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Protein sequence length:  2477
The length of the canonical sequence.

Location on the sequence:   RLPISRNTFAEVTGLSPGVT  Y YFKVFAVSHGRESKPLTAQQ
The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.

Residue conservation: 
The multiple alignment of the region surrounding the variant against various orthologous sequences.

Human                         RLPISRNTFAEVTGLSPGVTYYFKVFAVSHGRESKPLTAQQ

Mouse                         RLPVNRNTFAEITGLSPGVTYLFKVFAVHQGRESNPLTAQQ

Rat                           RLPVNRNTFAEVTGLSPGVTYLFKVFAVHQGRESKPLTAQQ

Bovine                        RLPVSRNTFAEVTGLSPGVTYHFKVFAVNQGRESKPLTAQQ

Horse                         RLPISRNTFAEVTGLSPGVTYHFKIFAVNHGRESKPLTGEQ

Chicken                       RLPITRSSFAEVVDLLPGTTYLFKIFAVSHGRESKPLTGEQ

Xenopus laevis                NLPVNRNTFAEVVNLQPGRTYSFEVYAVNRGQESEPLVGEF

Sequence annotation in neighborhood:  
The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.

TypePositionsDescription
Chain 32 – 2477 Fibronectin
Domain 909 – 998 Fibronectin type-III 4
DNA binding 907 – 1172
Alternative sequence 658 – 2477 Missing. In isoform 2 and isoform 16.
Beta strand 972 – 981


Literature citations

Mutations in FN1 cause glomerulopathy with fibronectin deposits.
Castelletti F.; Donadelli R.; Banterla F.; Hildebrandt F.; Zipfel P.F.; Bresin E.; Otto E.; Skerka C.; Renieri A.; Todeschini M.; Caprioli J.; Caruso R.M.; Artuso R.; Remuzzi G.; Noris M.;
Proc. Natl. Acad. Sci. U.S.A. 105:2538-2543(2008)
Cited for: VARIANTS GFND2 CYS-973; ARG-1925 AND ARG-1974; VARIANTS LEU-15 AND VAL-2051; CHARACTERIZATION OF VARIANTS GFND2 ARG-1925 AND ARG-1974;

Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.